Ginsenoside Rh3 is a natural product extracted from Panax ginseng C. A. Mey. Ginsenoside Rh3 treatment in human retinal cells induces Nrf2 activation.

Ginsenoside Rh3 inhibits UV-induced oxidative damages in retinal cells via activating Nrf2 signaling. Ginsenoside Rh3 treatment in retinal cells induces Nrf2 activation. The treatment with Ginsenoside Rh3 dose-dependently increases mRNA transcription and expression of key Nrf2-regulated genes, including HO1, NQO1, and GCLC. Consequently, protein expressions of these Nrf2-dependent genes (HO1, NQO1, and GCLC) are also significantly increased in Ginsenoside Rh3 (3-10?μM)-treated RPEs. Notably, although Nrf2 mRNA level is unchanged after Ginsenoside Rh3 treatment, its protein level is significantly increased by Rh3 [1]. Ginsenoside Rh3 (0.01, 0.1, 1 and 10 μM) shows no cytotoxic effect at all concentrations [2].

Ginsenoside Rh3 intravitreal injection (5? mg/kg body weight, 30 ?min pre-treatment) significantly attenuates light-induced decrease of both a- and b-wave amplitude. The electroretinography (ERG)'s a-wave decreases to 46.03±1.62% % of the control level after light exposure, which is back to 71.84±7.51% with Ginsenoside Rh3 administration. The b-wave is 40.19±3.34% of the control level by light exposure, and Rh3 intravitreal injection brings back to 80.01±2.37% of the control level [1].

SP-1 keratinocytes are seeded in 96 well plates (2×10^4 cells/well). After 24 h, the media is replaced with media containing various concentrations of (A) SKRG, or (B) Ginsenoside Rh3 (0.01, 0.1, 1 and 10 μM). Control cells are treated with DMSO at a final concentration of 0.1%. After 24 h, the media containing the compounds or DMSO is replaced with media containing 10% EZ-Cytox. The cells are then incubated at 37°C for 1 h, and the absorbance is measured using a microplate reader at a wavelength of 450 nm. All assays are performed in triplicate [2].

The BALB/c mice (male, 5-6 week old, 17-18?g weight) are used. The pupillary dilation is performed before exposure to 5000?lx of white fluorescent light. Thirty min before light exposure, Ginsenoside Rh3 (at 5 ?mg/kg body weight) is injected intravitreally to the right eye. ERG recording after light exposure is also reported early. The b-wave amplitude is measured from the trough of the a-wave to the peak of the b-wave, and the amplitude of the a-wave is measured from the initial baseline [1].

105558-26-7

C36H60O7

604.86

人参皂苷 RH3

Ethanol:25 mg/mL (41.33 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years